Skip to main content
SpringerLink
Log in

The Role of Atherosclerosis Imaging in Redefining Normal and Abnormal Cholesterol Values, and Risk Reduction in Primary Prevention Statin Trials

  • Published:
Current Atherosclerosis Reports Aims and scope Submit manuscript

Abstract

The emergence of atherosclerosis imaging, using coronary calcium scanning (CAC) and carotid intima media thickness (CIMT) and plaque as stronger predictors of cardiovascular events than risk factors of atherosclerosis, has created a paradigm shift in the primary prevention of cardiovascular disease. Rather than population-derived indices to define normal or abnormal low-density lipoprotein (or other lipid values) in the untreated individual patient, it is more appropriate to define “normal” as “cholesterol values at which level there is no subclinical atherosclerosis” and “abnormal” as “cholesterol values at which level there is subclinical atherosclerosis,” with the severity of “abnormal” depending on the degree of subclinical atherosclerosis. Similarly, the low-density lipoprotein treatment goal is the level at which atherosclerosis progression is halted. Extension of the subclinical atherosclerosis risk–based paradigms to primary prevention trials dramatically changes the manner in which trials should be conducted in the future, as well as the results of trials already performed. For example, asymptomatic patients with a CAC score of 0 have an extraordinarily low event rate but have been included in primary prevention statin trials even though their risk without treatment is very small. Reanalysis of the statin primary prevention trials after excluding the percentage (40%) of patients who would be expected to have a CAC score of 0 yields an absolute risk increase of 60% in both the placebo group (from 5.4% to 8.5%), and the statin group (from 3.0% to 4.8%). Absolute risk reduction increased by 58% (from 2.4% to 3.8%). Relative risk reduction of 44% was unchanged. In conclusion, 1) the presence or absence of atherosclerosis as measured by CAC redefines normal or abnormal lipid levels in an individual patient; 2) statin absolute risk reduction is significantly greater than previously appreciated; and 3) patients with a CAC score of 0 should be excluded from primary prevention randomized controlled trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Arad Y, Goodman KJ, Roth M, et al. Coronary calcification, coronary risk factors, and atherosclerotic cardiovascular disease events. The St. Francis Heart Study. J Am Coll Cardiol. 2005;46:158–65.

    Article  PubMed  CAS  Google Scholar 

  2. Budoff MJ, Shaw LJ, Liu ST, et al. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860–70.

    Article  PubMed  Google Scholar 

  3. Becker A, Leber A, Becker C, Knez A. Predictive value of coronary calcifications for future cardiac events in asymptomatic individuals. Am Heart J. 2008;155:154–60.

    Article  PubMed  Google Scholar 

  4. •• Detrano R, Guerci AD, Carr JJ, et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–1345. This landmark paper convincingly demonstrates the prognostic power of CAC and its superiority to risk factors.

    Article  PubMed  CAS  Google Scholar 

  5. •• Erbel R, Möhlenkamp S, Moebus S, et al, for the Heinz Nixdorf Recall Study Investigative Group. Coronary risk stratification, discrimination, and reclassification improvement based on quantification of subclinical coronary atherosclerosis. The Heinz Nixdorf Recall Study. J Am Coll Cardiol 2010;56:1397–1406. This is the most recent and comprehensive demonstration of the superiority of CAC to risk factors for risk assessment.

    Article  PubMed  Google Scholar 

  6. • Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk:The ARIC (Atherosclerosis Risk In Communities). Study.J Am Coll Cardiol 2010;55:1600–7. These are the most recent and powerful data supporting the superiority of carotid intima-media thickening and plaque to risk factors.

    Article  PubMed  CAS  Google Scholar 

  7. •• Taylor AJ, Cerqueira M, Hodgson JM, et al ACCF/SCCT/ACR/AHA/ASE/ASNC/SCAI/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. J Am Coll Cardiol 2010; 56: 1864 – 1894. This article defines the appropriate use of CAC.

    Article  PubMed  Google Scholar 

  8. •• Greenland P, Alpert JS, Beller GA, et al. 2010 ACCF/AHA Guideline for assessment of cardiovascular risk in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010;56:e50–103. This guideline is the latest and most powerful endorsement of subclinical atherosclerosis for risk assessment in primary prevention.

    Article  PubMed  Google Scholar 

  9. Friedewald VE, Ballantyne CM, Davidson MH, et al. The Editor’s Roundtable: Lipid management beyond statins—Reducing residual cardiovascular risk. Am J Cardiol. 2008;102:559–67.

    Article  PubMed  Google Scholar 

  10. Carey VJ, Bishop L, Laranjo N, et al. Contribution of high plasma triglycerides and low high-density lipoprotein cholesterol to residual risk of coronary heart disease after establishment of low-density lipoprotein cholesterol control. Am J Cardiol. 2010;106:757–63.

    Article  PubMed  CAS  Google Scholar 

  11. Roberts WC. It’s the cholesterol, stupid. Am J Cardiol. 2010;106:1364–6.

    Article  PubMed  Google Scholar 

  12. Raggi P, Davidson M, Callister TQ, et al. Aggressive versus moderate lipid-lowering therapy in hypercholesterolemic post-menopausal women: beyond endorsed lipid lowering with EBT scanning (BELLES). Circulation. 2005;112:563–71.

    Article  PubMed  CAS  Google Scholar 

  13. Arad Y, Spadaro LA, Roth M, et al. Treatment of asymptomatic adults with elevated coronary calcium scores with atorvastatin, vitamin C, and vitamin E. The St. Francis Heart Study randomized clinical trial. J Am Coll Cardiol. 2005;46:166–72.

    Article  PubMed  CAS  Google Scholar 

  14. Schmermund A, Achenbach S, Budde T, et al. Effect of intensive versus standard lipid-lowering treatment with atorvastatin on the progression of calcified coronary atherosclerosis over 12 months. A multicenter, randomized, double-blind trial. Circulation. 2006;113:427–37.

    Article  PubMed  CAS  Google Scholar 

  15. Raggi P, Callister TQ, Shaw LJ. Progression of coronary artery calcium and risk of first myocardial infarction in patients receiving cholesterol-lowering therapy. Arterioscler Thromb Vasc Biol. 2004;24:1–7.

    Article  Google Scholar 

  16. •• Budoff MJ, Hokanson JE, Nasir K, et al. Progression of coronary artery calcium predicts all-cause mortality. J Am Coll Cardiol Img 2010;3:1229 –1236. This article is a convincing demonstration of the importance of tracking CAC progression.

    Google Scholar 

  17. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian SimvastatinSurvival Study (4S). Lancet. 1994;344:1383–9.

    Google Scholar 

  18. Sacks FM, Moyé LA, Davis BR, et al. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the Cholesterol and Recurrent Events Trial. Circulation. 1998;97:1446–52.

    PubMed  CAS  Google Scholar 

  19. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349–57.

    Article  Google Scholar 

  20. Ridker PM, Danielson E, Fonseca FAH, et al. For the JUPITER study group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–207.

    Article  PubMed  CAS  Google Scholar 

  21. Espeland MA, Craven TE, Riley WA, et al. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Caroti Artery Progression Study Research Group. Stroke. 1996;27:480–5.

    Article  PubMed  CAS  Google Scholar 

  22. •• Hecht HS. Naghavi M. Cardiovascular residual risk assessment in patients undergoing therapy: A combined structural and functional approach. Current Cardiovascular Imaging Reports 2009, 2: 405–409. This article provides the theoretical framework for the redefinition of residual risk.

    Article  Google Scholar 

  23. Raggi P, Cooil B, Callister TQ. Use of electron beam tomography data to develop models for prediction of hard coronary events. Am Heart J. 2001;141:375–82.

    Article  PubMed  CAS  Google Scholar 

  24. Wong ND, Budoff MJ, Pio J, Detrano RC. Coronary calcium and cardiovascular event risk: evaluation by age- and sex-specific quartiles. Am Heart J. 2002;143:456–9.

    Article  PubMed  Google Scholar 

  25. Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37 month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107:2571–6.

    Article  PubMed  Google Scholar 

  26. Shaw LJ, Raggi P, Schisterman E, et al. Prognostic value of cardiac risk factors and coronary artery calcium screening for all cause mortality. Radiology. 2003;228:826–33.

    Article  PubMed  Google Scholar 

  27. Shemesh J, Morag-Koren N, Goldbourt U, et al. Coronary calcium by spiral computed tomography predicts cardiovascular events in high-risk hypertensive patients. J Hypertens. 2004;22:605–10.

    Article  PubMed  CAS  Google Scholar 

  28. Greenland P, LaBree L, Azen SP, et al. Coronary artery calcium score combined with Framingham score for risk prediction in asymptomatic individuals. JAMA. 2004;291:210–5.

    Article  PubMed  CAS  Google Scholar 

  29. LaMonte MJ, FitzGerald SJ, Church TS, et al. Coronary artery calcium score and coronary heart disease events in a large cohort of asymptomatic men and women. Am J Epidemiol. 2005;162:421–9.

    Article  PubMed  Google Scholar 

  30. Taylor AJ, Bindeman J, Feuerstein I, et al. Coronary calcium independently predicts incident premature coronary heart disease over measured cardiovascular risk factors: mean three-year outcomes in the Prospective Army Coronary Calcium (PACC) project. J Am Coll Cardiol. 2005;46:807–14.

    Article  PubMed  CAS  Google Scholar 

  31. •• Blaha M, Budoff MJ, Shaw LJ, et al. Absence of coronary artery calcification and all-cause mortality. J Am Coll Cardiol Img 2009;2:692–700. This article provides a definitive demonstration of excellent prognosis of patients with a CAC score of 0.

    Google Scholar 

  32. •• Sarwar A, Shaw LJ, Shapiro MD, et al. Diagnostic and prognostic value of absence of coronary artery calcification. J Am Coll Cardiol Img 2009;2:675–688. This article provides a definitive demonstration of excellent prognosis of patients with a CAC score of 0.

    Google Scholar 

  33. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ. 2009;338:b2376.

    Article  PubMed  CAS  Google Scholar 

  34. Shepherd J, Cobbe SM, Ford I, et al. For the west od scotland coronary prevention group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:301–7.

    Article  Google Scholar 

  35. Colhoun HM, Betteridge DJ, Durrington PN, et al. On behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS):multicentre randomised placebo-controlled trial. Lancet. 2004;364:685–96.

    Article  PubMed  CAS  Google Scholar 

  36. Knopp RH, d’Emden M, Smilde JG, Pocock SJ. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the atorvastatin study for prevention of coronary heart disease endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care. 2006;29:1478–85.

    Article  PubMed  CAS  Google Scholar 

  37. Sever PS, Dahlof B, Poulter NR, et al. For the ASCOT investigators. Prevention of coronary and stroke events with atorvastatin inhypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361:1149–58.

    Article  PubMed  CAS  Google Scholar 

  38. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The antihypertensive and lipid-lowering treatment to prevent heart attack trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. JAMA. 2002;288:2998–3007.

    Article  Google Scholar 

  39. John R, Downs JR, Michael Clearfield M, Weis S, et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615–22.

    Article  Google Scholar 

  40. Nakamura H, Arakawa K, Itakura H, et al. For the MEGA Study Group. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet. 2006;368:1155–63.

    Article  PubMed  CAS  Google Scholar 

  41. Khera A, de Lemos JA, Peshock RM, et al. Relationship between C-reactive protein and subclinical atherosclerosis: The Dallas Heart Study. Circulation. 2006;113:38–43.

    Article  PubMed  CAS  Google Scholar 

  42. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention. A Meta-analysis of 11 randomized controlled trials involving 65, 229 participants. Arch Intern Med. 2010;170:1024–31.

    Article  PubMed  CAS  Google Scholar 

Download references

Disclosure

H. Hecht is a consultant for and has received payment for development of educational presentations from Philips Medical Systems.

Author information

Authors and Affiliations

  1. Lenox Hill Heart and Vascular Institute, 130 E. 77th St., New York, NY, 10021, USA

    Harvey S. Hecht

Authors
  1. Harvey S. Hecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Harvey S. Hecht.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hecht, H.S. The Role of Atherosclerosis Imaging in Redefining Normal and Abnormal Cholesterol Values, and Risk Reduction in Primary Prevention Statin Trials. Curr Atheroscler Rep 13, 422–430 (2011). https://doi.org/10.1007/s11883-011-0194-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11883-011-0194-z

Keywords

Search

Navigation